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A rapid LC-MS/MS method for quantification
of CSUOH0901, a novel antitumor agent, in rat
plasma
Ramakrishna R. Voggu, Ravali Alagandula, Xiang Zhou, Bin Su,
Bo Zhong and Baochuan Guo*
ABSTRACT: CSUOH0901, a novel anticancer derivative of nimesulide, exhibits very promising anticancer activities in various
cancer cell lines. In order to support further pharmacological and toxicological studies of this promising anticancer drug can
didate, an LC-MS/MS method was developed and validated in accordance with the US Food and Drug Administration guidelines. The drug molecules were extracted from plasma samples by protein precipitation and then analyzed with LC-ESI-MS/
MS. An excellent analyte separation was achieved using a phenomenex C18 column with a mobile phase of 90% methanol
and 5 mM of ammonium formate. The validated linear dynamic range was between 0.5 and 100 ng/mL and the achieved correlation coefficient (r2) was >0.9996. The results of inter- and intra-day precision and accuracy were satisfactory, that is,
<12% for accuracy and within ±5% for precision at a low and high quality control concentrations, respectively. In addition,
the analyte and internal standard (JCC76) were found to be stable under the storage conditions at — 20°C for about 2 months.
Hence, the acquired results proved that the LC-ESI-MS/MS method developed is precise, accurate and selective for the quantification of CSUOH0901 in plasma, and can be used for pharmacokinetic studies. Copyright © 2014 John Wiley & Sons, Ltd.
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CSUOH0901 {benzo [1,3] dioxole-5-carboxylicacid [3-(2,5-dimethylbenzyloxy)-4-(methanesulfonylmethylamino)-phenyl] amide}
(NSC751382; Fig. 1C; Zhong et a!., 2013) is a novel, secondgeneration anticancer agent derived from nimesulide, which
can inhibit cyclooxygenase-2 (COX-2; Fig. 1 A). In cancer therapy,
nimesulide showed hepatotoxicity on long-term usage and required higher concentrations to inhibit COX-2 activity (Zhong
et al., 2012). This led to the development of CSUOH0901, a
nimesulide derivative, which exhibited very promising anticancer
activities by interacting with tubulin and Hsp27 proteins, which
are important to cancer cell proliferation. CSUOH0901 inhibited
the proliferation of cancer cells of lung, breast, colon, CNS, ovary,
renal and prostate cancer with an IC50 of 0.1-0.5 μm, which is 10fold more active than JCC76 {N-[3-(2,5-dimethylbenzyloxy)-4(methylmethylsulfonamido) phenyl] cyclohexanecaboxamide;
(Fig. 1B; Suleyman et al., 2008} and 1000-fold more potent than
nimesulide (Zhong et al., 2013).
Recent docking studies in SKBR-3 breast cancer cell lines
(Suleyman et al., 2008; Yi et al., 2012) revealed that CSUOH0901
interacted with both α- and β-tubulin in the colchicine pocket
and disorganized microtubules. Additionally, interaction of heat
shock protein 27 (Hsp27) (Sun and MacRae, 2005) with
CSUOH0901 inhibited the phosphorylation of Hsp27, leading to
cell apoptosis. Hsp27 is a stress protein that is expressed when
cells are stimulated by heat (Kampinga et al., 1995; Stege et al.,
1995a, 1995b), radiation (Rau et al., 1999), chemotherapeutic
drugs (Ciocca et al., 1992) or other agents (Wu and Welsh,
1996). A recent study showed that cancer cells with HSP27 overexpression were resistant to chemotherapeutic drugs (Huot

et al., 1991; Fuqua et al., 1994; Hettinga et al., 1996; Richards
et al., 1996). Antisense to inhibition of the HSP27 gene decreased cellular resistance to chemotherapy as well as to heat
shock (Horman et al., 1999). Other studies have suggested that
HSP27 prevents cancer cells from apoptosis and dramatically enhances their tumorigenicity (Garrido et al., 1998, 1999; Guenal
et al., 1997; Samali and Cotter, 1996). Mass spectrometric studies
revealed that tubulin and Hsp27 proteins are the most prevalent
targets of CSUOH0901. Recent in vivo studies demonstrated that
CSUOH0901 significantly decreased the size of HT29 tumors in a
xenograft model compared with the control group, suggesting
the low toxicity and high potency in vivo (Zhong et al., 2012).
Clearly, CSUOH0901 is a very promising anticancer drug candidate and will be further studied. However, to date, no LCMS/MS method has been developed for the quantification of
CSUOH0901. Therefore, a simple and accurate method to quantify CSUOH0901 is needed that will be essential to the future
pharmacological and toxicological studies of CSUOH0901. In this
work, a rapid and sensitive LC-MS/MS method was developed
and validated for quantitative determination of CSUOH0901 in
rat plasma. We demonstrated that the method developed was

Sample extraction
Plasma samples were removed from the -20°C freezer and thawed to
room temperature. Single and double blanks were prepared by spiking
10 μL of acetonitrile in 200 μL of rat plasma. Then 10 μL of IS working
solution was spiked in all calibration, QC solutions and single blank, except in double blank and vortexed immediately for 30 s. The samples
were deproteinized by adding 800 pL of acetonitrile and sonicated for
15 min followed by centrifugation at 13,000g for 15 min. The supernatants were transferred into autosampler vials for LC-MS/MS analysis.

LC-MS/MS analysis
LC-MS/MS analysis was conducted using 5500 QTRAP triple quadrupole,
tandem mass spectrometer (AB Sciex, Toronto, Canada) with an
electrospray ionization (ESI) source (Framingham, MA, USA) interfaced with
high-performance liquid chromatography (HPLC, Shimadzu, Columbia, MD,
USA) with two LC-30 AD pumps, DUG-20A3R inline degasser, a SIL-30 AC
autosampler, a CBM-20A controller and a CTO-10AVP column oven
(Shimdazu, Tokyo, Japan). Analyst software, version 1.5.2 (AB Sciex) was
used to control all the parameters of tandem mass spectrometer and HPLC.

CSUOH0901
Figure 1. The chemical structures of nimesulide (A), internal standard
JCC76 (B) and CSUOH0901 (C).

fast, sensitive and specific for quantifying CSUOH0901 in plasma,
and can be used in pharmacological studies.

Experimental
Chemical and reagents
CSUOH0901 and JCC76 (internal standard, IS) were synthesized and purified according to the previously published procedures (Zhong et al.,
2013; Suleyman etal., 2008). HPLC-grade methanol and acetonitrile were
purchased from Pharmco-Apper (Philadelphia, PA, USA). Formic acid,
ammonium formate and ammonium acetate were purchased from
Sigma Aldrich Chemical Company (Allentown, PA, USA). Dimethyl sulfoxide was obtained from Fisher Scientific (Pittsburgh, PA, USA). Deionized
water was generated from a Barnstead Nano Pure Water Purification System from Thermo Scientific (Waltham, MA, USA). Sprague-Dawley rat
plasma K2 with specific lot numbers (10577-01-06) was purchased from
Innovative research (Novi, Ml, USA).

Calibration standard and quality control samples
Preparation of stock and working solutions. The stock solutions of
CSUOH0901 and JCC76 (IS) were prepared in dimethyl sulfoxide (DMSO)
at 1 mg/mLand stored at -20°C. A set of CSOH0901 working solutions of
10, 20, 50, 150, 400, 1000 and 2000 ng/mL were prepared by serial dilution from the stock solution with DMSO. The working solution of JCC76
(IS) was obtained by diluting the stock solution with DMSO to give a concentration of 150 ng/mL.
Preparation of calibration and quality control plasma samples. The
calibration plasma solutions were prepared by spiking 10 μL of
CSUOH0901 working solutions in 200 μL of blank plasma (mixture of 6
lots) to give drug concentrations of 0.5, 1.0, 2.5, 7.5, 20, 50 and 100
ng/mL. The lower limit of quantification (LLOQ) and quality control (QC)
standards were prepared in a similar way at 0.5, 1.25, 10, 80 ng/mL,
representing LLOQ, low QC (LQC), middle QC (MQC) and high QC (HQC)
respectively. The QC and calibration samples were frozen at -20°C overnight, and then treated by the following sample preparation procedure
and subjected to LC-MS/MS analysis.
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A Luna C18 (2) HPLC column (50 x2.0 mm 5 μm) with a C18 security
guard cartridge from Phenomenex (Torrance, CA, USA) was used for
the chromatographic separation of the supernatants from the
deproteinized samples. An optimized gradient flow of mobile phase A,
5 mM ammonium formate in 2% methanol, and mobile phase B, 5mM
ammonium formate in 90% methanol at a flow rate of 0.2 mL/min, was
developed. The column was equilibrated with the mobile phase for 10
min and the run time was 8 min for each run with 10 μL injection volume. The positive ESI mode was selected and the MRM (multiple reaction monitoring) function was used for quantification, with the
transitions set at mlz 483.2 >404.3, m/z 483.2 —>119.0 for CSUOH0901
and m/z 445.3 —>366 .3 for JCC76 (IS) (Fig. 2). The dwell time for each
MRM transition was set at 120 ms. Source dependent parameters were
optimized by flow infusion analysis: nebulization gas (30), heating gas
(30), curtain gas (40), ion spray voltage (5000 eV) and temperature
(450°C). Compound dependent parameters were manually optimized
as following: declustering potential, 180; entrance potential, 10; collision
energy, 20; and cell exit potential, 12.

Analytical method validation
A full method validation was performed using rat plasma according to
the currently accepted FDA bioanalytical method guidelines (US Food
and Drug Administration, 2001) and also other references (Liu et al.,
2013; Ito et al., 2013). The entire method was validated for precision, accuracy, linearity, selectivity, extraction recovery, LLOQ, matrix effect and
stability studies.
Calibration curve, linearity and sensitivity. Seven CSUOH0901
plasma calibrators at the concentrations of 0.5, 1.0, 2.5, 7.5, 20, 50 and
100 ng/mL, double blank and single blank (only JCC76 internal standard)
were selected to establish a calibration curve. The weighed linear regression, 1/x, as weighing factor was used to calculate the slope and correlation coefficient of the calibration curve. The LLOQ was defined as the
concentration with precision (coefficient of variation, CV) <20%.

Accuracy and precision. Intra- and inter-assay precision and accuracy
studies were performed using three QC standards, LQC, MQC and HQC,
at 1.25, 10 and 80 ng/mL with five replicates (n =5). Intra- and inter-assay
precisions were determined as CV, and accuracies were calculated by
comparing experimentally determined concentrations with the spiked
values. Therefore, accuracy (%) = [(experimental concentration - spiked
concentration)/ spiked concentration] x 100.

Recovery and matrix effect. The absolute extraction recovery was
determined by comparing the peak areas of CSUOH0901 in QC samples
at 1.25, 10 and 80 ng/mL (CSUOH0901 added prior to deproteinization)
with those of postextraction samples (CSUQH0901 added after

Figure 2. Precursor/product ion spectra and proposed fragmentation pathways for internal standard JCC76 (A) and analyte CSUOH0901 (B).

deproteinization) of corresponding concentrations. The relative recovery
was determined by comparing peak area ratio of CSUOH0901 and IS
(JCC76) spiked in plasma before extraction with that in postextraction
spiked samples.
The absolute matrix effect was calculated by comparing the peak
areas of postextraction blank plasma samples spiked with CSUOH0901
(1.25, 10 and 80 ng/mL) with those of corresponding standard solutions
at equivalent concentrations. The relative matrix effect was calculated by
comparing the peak area ratio of CSUOH0901 and IS (JCC76) spiked in
the blank plasma postextraction solution with that in standard solution.

Stability studies
Effect of freeze-thaw on CSUOH0901 in plasma. Two QC samples
of 1.25 and 80 ng/mL concentrations were selected to verify their stability. The stability test for CSUOH0901 in plasma was studied after three
freeze-thaw cycles over a 3 day period.
Short- and long-term stability studies of analyte in plasma. The
stability studies of CSUOH0901 in rat plasma were performed using
two QC standards (1.25 and 80 ng/mL), which were kept under different
storage conditions: 10 h at room temperature and 6 months at -20°C,
before and after sample extraction.

Optimization of mass spectrometric conditions for IVIRM
quantitation
Positive ionization mode was selected to detect and optimize the
MS parameters for the detection of both CSUOH0901 and JCC76
(internal standard). It was found that the standard CSUOH0901
and JCC76 solutions prepared in methanol-water (9:1, v/v)
yielded higher intensity when compared with the solutions prepared in acetonitrile-water (9:1, v/v). Fragmentation led to the
formation of daughter ions in the product ion scan mode (Fig. 2).
Based on the fragmentation study, the MRM transitions of m/z
483.2 —>404.3 for CSUOH0901 and 445.3 ->366.3 for JCC76 were
selected for quantification, as these product ions yielded strong
signals. The highest MS signal was obtained by fine-tuning collision energy, spray voltage and ion source temperature.

Optimization of HPLC conditions
To overcome the irreproducibility and matrix effect problems associated with the isocratic flow, a gradient flow of mobile phase
A, 5mM ammonium formate in 2% methanol, and mobile phase
B, 5 mM ammonium formate in 90% methanol with 0.2 mL/min
flow rate, was employed. This gradient flow improved the sensitivity and signal-to-noise ratio with a total run time of 18 min.
High concentration of methanol was used to elute CSUOH0901
from C18 column, owing to its low solubility in water with
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Stability of analyte in stock solutions. The stability studies of stock
solutions and working solutions of CSUOH0901 and internal standard
(JCC76) were also evaluated. The stock solutions of analyte were stored
at -20°C for 7 months. Two QC standards of concentrations 1.25 and
80 ng/mL were prepared from both the stored and fresh stock solutions
and the experimentally determined concentrations of CSUOH0901 were
compared (n =3 for each sample).

Results and discussion

Figure 3. (A) Multiple reaction monitoring chromatograms of blank rat plasma in both IS and analyte windows. (B) IS JCC76 (10 ng/mL, 5.58 min) and
CSUOH0901 at LLOQ level (0.5 ng/mL, 5.10 min).

predicted logD value of 4.86. The intensity of CSUOH0901 was
increased 2-fold when 5 mM ammonium formate buffer was
used in the mobile phases and the retention times were around
5.09 min for CSUOH0901 and 5.58 min for JCC76 (IS) (Fig. 3B).

blank signal (Fig. 3). The lowest concentration in a calibration
curve (LLOQ) was quantified with the accuracy and precision
within 15% (Table 1).

Table 1. Accuracy and precision of CSUOH0901 calibration
standards (n =5) over 0.5-100 ng/mL

Linearity, sensitivity, selectivity and LLOQ
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the Calibration curve for CSUOH0901 in plasma was linear in the
range of 0.5-100 ng/mL. Linearity results showed the quadratic
fit for CSUOH0901 with a seven-point calibration curve of concentrations 0.5, 1.0, 2.5, 7.5, 20, 50 and 100 ng/mL including
double-blank and single-blank (only JCC76 internal standard)
plasma samples. An excellent linearity was obtained with the
correlation coefficient of 0.9996 and the linear regression equation was y =0.073x —0.0085. This method exhibited high selectivity with no interfering peak in six different blank plasma
samples from different sources. The LLOQ was found to be 0.5
ng/mL, where the signal intensity was 20-fold higher than the

Nominal
concentration

(ng/mL)

0.5
1
2.5
7.5
20
50
100

Determined
concentration

Accuracy

Precision

(ng/mL)

(RE)

(CV)

0.49 ±0.01
0.90 ±0.09
2.58 ±0.08
7.23 ±0.27
20.42 ±0.42
49.14 ±0.86
97.30 ±2.70

-2.0%
-10.0%
3.2%
-3.6%
2.1%
-1.7%
-2.7%

4.5%
6.0%
6.7%
11.0%
1.7%
1.6%
2.2%

Table 2. Inter- and intra-assay accuracy and precision of CSUOH0901 in rat plasma
Inter- assay

Intra- assay
Spiked
(ng/mL)
1.25
10
80

Determined
(ng/mL)

Accuracy
(%RE)

SD

Precision
(CV)

Determined
(ng/mL)

Accuracy
(RE)

SD

Precision
(CV)

1.39
10.26
78.52

11.2%
2.6%
-1.9%

0.04
0.18
1.44

2.9%
1.8%
1.8%

1.39
10.35
79.58

11.2%
3.5%
-0.5%

0.07
0.46
4.36

5.0%
4.5%
5.5%

Accuracy and precision

Table 4. Stabilities of CSUOH0901 under various conditions

Intra- and inter -assay accuracies of the validated method ranged
from 1.9 to 11.2% and from 0.5 to 11.2%, respectively. The intraand inter-assay precision values ranged from 1.8 to 2.9% and
from 4.5 to 5.5%, respectively. The inter- and intra-assay accuracy
and precision of the QC samples are depicted in Table 2.

Extraction recovery and matrix effect
The absolute recoveries of the extraction method were 104.0,
105.0 and 104.0% for the QC standards at 1.25, 10, and 80
ng/mL, and the relative recoveries of the extracted method were
99.9, 96.1 and 97.7% for the QC standards at 1.25, 10, and 80
ng/mL, respectively, as indicated in Table 3. Absolute matrix effects for each of three plasma samples at 1.25, 10, and 80
ng/mL were 5.5, 8.1 and 9.9%, and relative matrix effects were
2.6, 5.1 and 12.4% indicating the minimal matrix effect. Hence,
the protein precipitation technique for sample preparation was
found to be effective, as it not only extracted the analyte and internal standard well but also removed impurities causing interferences from the sample matrix.
Performing MRM confirmed the absence of significant matrix
effect by comparing the peak areas ratio of CSUOH0901 MRM
transitions (MRM1, m/z 483.2 —>404.3; and MRM2, m/z 483.2
—>119.0) for the spiked rat plasma samples with the average
peak area ratio for seven calibrators:
MRM ratio = peak area MRM1/peak area MRM2

(1)

The average MRM ratio of the seven calibrators was 1.5 ±1.9
(±SD). This confirmed the absence of matrix effect in the plasma
samples and that they are in the acceptable range.

CSUOH0901 was stable for at least 8 h at room temperature
(bench top) and for 10 h when postextracted at room temperature and the results were summarized in Table 4. The recovery of

Table 3. Absolute and relative matrix effect and recovery of
CSUOH0901 in rat plasma

1.25
10
80

Concentration
(ng/mL)

Recovery
(%)

Bench-top (8 h)
At room temperature

1.25
80.00

112.0%
99.1%

Freeze-thaw (three cycles)

1.25
80.00

112.0%
104.5%

Post-extraction (10 h) at room
temperature

1.25
80.00

106.4%
97.8%

Table 5. Stabilities of CSUOH0901 and JCC76 Stock solutions
after storage at —20°C for 6 months

Type of solutions
CSUOH0901 stock solution
JCC76 stock solution
CSUOH0901 working solution
JCC76 working solution

Concentration Recovery (%)
1 mg/mL
1 mg/mL
25 ng/mL
1600 ng/mL
150 ng/mL

111.8%
106.0%
99.6%
105.0%
124.6%

CSUOH0901 was 112.0% at LQC and 104.5% at HQC levels after
three freeze-thaw cycles. Stability studies of stock solutions and
working solutions of CSUOH0901 and internal standard (JCC76)
were performed by storing them at —20°C for at least 6 months.
The analyte and the internal standard were found to be stable in
stock solutions and the results are summarized in Table 5.

Conclusion

Stability

Concentration
or QC sample;
(ng/mL)

Stability

Matrix effect

In conclusion, a highly sensitive LC-MS/MS method for the quantitation of CSUOH0901 in rat plasma was developed and validated for the first time. The method developed has a short run
time of 18 min employing a simple one-step sample preparation.
The accuracy and precision were <10% and the LLOQ was as
low as 0.5 ng/mL. The results from the validation studies illustrated that this method can be used to determine the pharmacological and toxicological profiles of CSUOH0901 in rats.

Recovery

Absolute

Relative

Absolute

Relative

5.5%
8.1%
9.9%

2.6%
5.1%
12.4%

104.0%
105.0%
104.0%

99.9%
96.1%
97.7%
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